张发明，男，1964年生，博士，武汉大学药学院教授、 博士生导师 。

1980 – 1984武汉大学，化学学士；

1984-1987武汉大学，物理化学硕士；

1987-1990中科院生物物理研究所，生物化学博士；

1990-1993美国德克萨斯大学西南医学中心从事博士后研究工作；

1994-2005美国礼来制药公司，高级科学家和药物新药开发部主管；

2005-2008美国印地安纳大学化学和生物化学系任副教授；

2008-2010中美冠科生物医药有限公司总裁；

2012 - 至今 武汉大学药学院教授。

具有20多年生物医药的研发经验，特别是在蛋白质和基因工程药物研发方面卓有成就

有2篇论文以第一作者在《NATURE》上发表，7项药物设计及优化的美国专利。在Eli Lilly & Co.任职11年期间，主持或参与完成了多部药政法规和药品研发指南性文件的编写，为美国食品和药品审评工作框架的制订做出了重要贡献。同时，张发明教授致力于企业管理和药品的全球联合研发、推动行业ISO标准、参与国际药品标准的协调，尝试多国晋级申报，领衔海外融资生产，发展三板块市场合作等一系列中国医药研发能力提升和产品国际化的战略实践。2009年第一批武汉市“3551人才计划”入选者。

1. Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, Ratnam M, Zhang F, Dann CE . Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15180-8.

2. Rogers T, Li P, Smiley D, DiMarchi RD, and Zhang F., (2007), Design, synthesize and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jul 1;63(Pt 7):599-601.

3. Singh J, Ling L, Sawyer JS, Lee W, Zhang F, Yingling JM., (2005), Successful discovery of TbRI (ALK5) kinase inhibitors using HTS, target-hopping and virtual screening, Chemistry Today, 23 (3): 35-38.

4. Hamdouchi C, Zhong B, Mendoza J, Zhang F et al. (2005), Structure-Based Design of a New Class of Highly Selective Aminoimidazo[1,2-á]pyridine-Based Inhibitors of Cyclin Dependent Kinases, bioorganic & Medicinal Chemistry Letters. 15 (7): 1943-1947.

5. Jaramillo C, Zhang F. et al (2004), Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation, bioorganic & Medicinal Chemistry Letters. 14(24): 6095-6099.

6. J. Singh, J. Yingling, Zhang F, et al (2004), Transforming the TGF-â pathway: Convergence of distinct lead generation strategies on a novel kinase pharmcophroe for TbRI, Current Opinion in Drug Discovery and Development 7(4): 10-20.

7. Al-Awar RS, Ray JE, Zhang F. etal (2004). Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors. Bioorg Med Chem Lett. 14(15): 3925-3928.

8. Sawyer JS, Beight DW, Zhang F, Yingling JM (2004). Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett. 14(13): 3581-3584.

9. Hadouchi C, Keyser H,Zhang F, Brooks H, et al (2004). The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo(1,2-a)pyridines. Molecular Cancer Therapeutics. 3(1):1-9

10. Vincent J.-P, Johnson RB, Parsons S, Zhang F, Wang QM (2003). Identification of a C-terminal regulatory motif in hepatitis C virus RNA-dependent RNA polymerase: structural and biochemical analysis. J. Virology. 77: 9020-9028

11. Sanchez-Martinez C, Shih C, Zhu G, Dempsey JA, Zhang F(2003) . Studies on Cyclin Dependent Kinase Inhibitors:Indolo[2,3-a]pyrrolo[3,4-c]carbazoles versus Bis-indolylmaleimides, Bioorganic & Medicinal Chemistry Letters 13:3841-3846.

12. Vieth M, Brooks H, Hamdouchi C, McMillen W, Sawyer JS, Yingling J, and Zhang F(2003). Combining Medicinal Chemistry with Chemogenomic and Computer-Aided Structure-Based Design in Development of Novel Kinase Inhibitors, Cell. Mol. Biol. Lett 8 (2A):566-567

13. Sawyer JS,Herron DK,Edward CR, Zhang F, and Yingling J (2003). Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-beta Type I Receptor Kinase Domain. Journal of Medicinal Chemistry 46 (19):3953-3956.

14. Wang QM, Hockman M, Staschke K, Zhang F, Parsons S (2002). Oligomerization and Cooperative RNA Synthesis Activity of HCV RNA-Dependent RNA Polymerase, J. Virology. 76:3865-3872

15. Jin L, Briggs S, Clawson D, Schevitz R, Smiley D, Tashjian A, Zhang F (2000). “Crystal Structure of Human Parathyroid Hormone 1-34 at 0.9 Å Resolution”, J. Biol. Chem. 275:27238-27244.

16. Zhang F, Basinski M, DiMarchi RD et al. (1997) “Crystal Structure of the Obese Protein Leptin-E100”, Nature387:206-209

17. Zhang J, Zhang F, Ebert D, Cobb MH, and Goldsmith EJ(1995) “Activity of the MAP Kinase ERK2 is Controlled by a Flexible Surface Loop”, Structure 3:299-307.

18. Zhang F, Strand A, Robbins D, Cobb MH, and Goldsmith EJ (1994) “Crystal Structure of MAP kinase ERK2 at 2.3Å Resolution”. Nature. 367: 704-711.

19. Zhang F, Robbins D, Cobb MH and Goldsmith EJ (1993) “ Crystallization and Preliminary X-ray Studies of Extracellular Signal-regulated Kinase-2/MAP kinase with an Incorporated His-tag”. J. Mol.Biol. 233: 550-552.

20. Lin Z, Li J , Zhang F and Tsou C-L (1993) “Structure of D-Glyceraldehyde-3-phosphate Dehydrogenase from Palinurus Versicolor Carrying the fluorescent NAD Derivatives at 2.7 Å Resolution” Arch. Biochem. Biophy. 302:161-166.

21. Zhang F, Kobe B, Stewart CB, Rutter W and Goldsmith EJ (1991) “ Structural Evolution of an Enzyme Specificity: The Structure of Rat Carboxypeptidase A2 at 1.9 Å Resolution”. J. Biol. Chem. 266: 24606-24612.

1. Faming Zhang, John Beals, etal. (1997) “Obese Protein: Three-Dimensional Structure, Surface Properties, and Receptor-Binding Model”. In Leptin: The Voice of Adipose Tissue, W.F. Blum/W.Kiess/W.Rascher Eds. Edition J & J, 25-31.

2. Lei Jin, Armen Tashjian, and Faming Zhang (2003), “ Toward an Understanding of Human Parathyroid Hormone (PTH) Structure and Function”, in Parathyroid Hormone Molecular Biology, Tally Nareh/Justin Silver Eds. Landes Bioscience.

3. Faming Zhang, figure and text (21-23) contributions to college textbook “Fundamentals of Biochemistry”, 2/e by Voet and Pratt, John Wiley & Sons.

4. Faming Zhang, figure and text contributions to: Growth Hormone Replacement Therapy in Adults with Hypopituitary Disease. V1.1.

5. John Mayer, Faming Zhang, Richard DiMarchi (2007) “Insulin Structure and Function” , Biopolymers, April 4.